XenoGesis and Juniper Pharma Services Strengthen Alliance
News Oct 19, 2017
XenoGesis and Juniper Pharma Services have extended their strategic alliance around their Enabling Technologies Rapid Screen through the addition of the gold standard PBPK modelling and simulation software, GastroPlusTM.
This expanded partnership brings greater understanding of a compound’s potential exposure in both preclinical and clinical studies. Jointly they are already working in collaboration on a number of client projects using these combined technologies.
Claire Madden-Smith, SVP at Juniper Pharma Services, said: “We are delighted to be further strengthening our relationship with XenoGesis with their addition of GastroPlusTM. Our combined offering provides our clients unique access to development and DMPK expertise that is truly advancing programmes smartly and rapidly.”
GastroPlusTM is a software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data to be integrated within the context of a virtual animal or a human model. Having this in-silico understanding can help make faster and more informed development decisions. It has been identified as the number one commercially ranked program for in vitro – in vivo extrapolation and has been the focus of several publications from the FDA.
Richard Weaver, Managing Director at XenoGesis, added: “We continue to invest in the best technology and systems to support our clients and help them to achieve greater success in their drug discovery projects. We work closely with our partner at Juniper Pharma Services, to bring GastroPlusTM and their Enabling Technologies Rapid Screen together to offer a unique service to our joint clients.”
One of the largest challenges of bringing new medicines to market is reducing the rates of attrition due to lack of efficacy and safety profile of a compound, whilst managing costs. Attrition in the pharma industry remains high at around 90% from Phase 1 to launch of a novel drug.
XenoGesis specialises in DMPK, the science of understanding the potential exposure and effect in patients, and having that knowledge at a very early stage in the development work undertaken by Juniper can increase the likelihood of success, whilst saving time and money.
Graham Trevitt, Director of DMPK, Consultancy, Modelling & Simulation at XenoGesis, said: “For researchers in the life sciences sector, it is difficult to measure everything as a project winds its way through the R&D process. Data that is generated is often difficult to interpret, yet expected to inform speedy decisions that influence the drug development project. Making the wrong decision can be costly in terms of time and money. GastroPlusTM gives our clients access to a gold standard tool that will help them understand the potential exposure of a compound in both pre-clinical and clinical studies. By integrating PK-PD data, this allows prediction of efficacious doses.”
Availability of Brain Tumor Surgery Dye Increases for NHS PatientsNews
A chemical dye that lights up brain tumours during surgery should be available to more NHS patients in England, according to the National Institute for Health and Care and Excellence (NICE).READ MORE